1例盐酸曲美他嗪片致合并肾功能不全老年患者帕金森综合征的药学监护

doi:10.19803/j.1672-8629.20220211

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (3): 343-345.
DOI: 10.19803/j.1672-8629.20220211

1例盐酸曲美他嗪片致合并肾功能不全老年患者帕金森综合征的药学监护

张渊, 贺梅^*

毕节市第一人民医院,贵州毕节 551700

收稿日期:2022-04-29 出版日期:2023-03-15 发布日期:2023-03-17
通讯作者: ^* 贺梅,女,硕士,主任药师,医院药学。E-mail：672262298@qq.com
作者简介:张渊,男,硕士,主管药师,心血管临床药学。
基金资助:
贵州省卫生健康委科学技术基金项目（gzwkj2021458）; 贵州省毕节市第一人民医院临床药学与药物研究重点实验室项目（毕科合字〔2019〕1号）

Pharmaceutical care for a case of Parkinson's syndrome caused by trimetazidine hydrochloride tablets in an elderly patient with renal insufficiency

ZHANG Yuan, HE Mei^*

Department of Clinical Pharmacy, Bijie First People's Hospital, Bijie Guizhou 551700, China

Received:2022-04-29 Online:2023-03-15 Published:2023-03-17

摘要/Abstract

摘要： 目的探讨肾功能不全老年患者使用盐酸曲美他嗪片致帕金森综合征的原因和机制,为临床合理使用盐酸曲美他嗪片提供参考。方法分析1例患者接受盐酸曲美他嗪片治疗后的诊疗过程,并进行相关文献回顾。结果患者接受盐酸曲美他嗪片治疗后第2天出现帕金森综合征,予以停用盐酸曲美他嗪片后患者帕金森综合征消失。结论盐酸曲美他嗪片致肾功能不全老年患者帕金森综合征风险高,治疗中应加强监护。

关键词: 盐酸曲美他嗪片, 帕金森综合征, 肾功能不全, 老年患者, 药品不良反应

Abstract: Objective To investigate the causes and mechanisms of parkinsonism induced by trimetazidine hydrochloride tablets in elderly patients with renal insufficiency, and to provide reference for rational clinical use of trimetazidine hydrochloride tablets. Methods The course of treatment of one patient after taking trimetazidine hydrochloride tablets was analyzed while related literature was reviewed. Results Parkinsonism occurred one day after treatment with trimetazidine hydrochloride tablets, but disappeared when these tablets were discontinued. Conclusion Trimetazidine hydrochloride tablets may increase the risk of parkinsonism in elderly patients with renal insufficiency and should be monitored during clinical use.

Key words: trimetazidine dihydrochloride tablets, parkinsonism, renal insufficiency, elderly patients, adverse drug reaction

中图分类号:

R972
R969.3

张渊, 贺梅. 1例盐酸曲美他嗪片致合并肾功能不全老年患者帕金森综合征的药学监护[J]. 中国药物警戒, 2023, 20(3): 343-345.

ZHANG Yuan, HE Mei. Pharmaceutical care for a case of Parkinson's syndrome caused by trimetazidine hydrochloride tablets in an elderly patient with renal insufficiency[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 343-345.

参考文献

[1] MARZILLI M, VINEAREANU D, LOPASCHUK G, et al.Trimetazidine in cardiovascular medicine[J]. International Journal of Cardiology, 2019, 293: 39-44.
[2] DY AMB, LIMJOCO LLG, JAMORA RDG.Trimetazidine-induced parkinsonism: a systematic review[J]. Frontiers in Neurology, 2020, 11(44): 1-6.
[3] DÁVID P, DÁNIEL B, ANDRÁS Aet al. Trimetazidine use in parkinson’s disease: is it a resolved problem?[J]. eNeuro, 2021, 8(3): 0452-20.2021.
[4] ZHENG FY, WU Y, RAO YF, et al.The role of the Naranjo’s scale in the evaluation of adverse drug reactions and an example analysis[J]. Chinese Journal of Pharmacy(中国药学杂志), 2012, 47(8): 650-652.
[5] BONDON-GUITTON E, PEREZ-LLORET S, BAGHERI H, et al.Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France[J]. Movement Disorders, 2011, 26(12): 2226-2231.
[6] WENNING GK, KIECHL S, SEPPI K, et al.Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study[J]. The Lancet Neurology, 2005, 4(12): 815-820.
[7] PINTER D, KOVACS M, HARMAT M, et al.Trimetazidine and parkinsonism: a prospective study[J]. Parkinsonism and Related Disorders, 2019, 62(1): 117-121.
[8] THANYI B, TREADWELL S.Drug induced parkinsonism: a common cause of parkinsonism in older people[J]. Postgraduate Medical Journal, 2009, 85(1004): 322-328.
[9] MARTI MASSO JF.Parkinsonismo por trimetazidina[J]. Neurologia, 2004, 19(7): 392-397.
[10] MEI LL, REN F, ZHANG WF, et al.Research progress of Parkinson syndrome associated with trimetazidine[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2020, 22(12): 689-692.
[11] SIVET J, GASTINE B, MOSQUET B, et al.Trimetazidine-induced encephalopathy with choreiform disorders: a case report[J]. La Revue De Médecine Interne, 2008, 29(6): 512-515.
[12] BARRE J, LEDUDAL P, OOSTERHUIS B, et al.Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure[J]. Biopharmaceutics & Drug Disposition, 2003, 24(4): 159-164.
[13] MASMOUDI K, MASSON H, GRAS V, et al.Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases[J]. Fundam Clin Pharmacol, 2012, 26(2): 198-203.
[14] FABIANI G, PASTRO PC, FROEHNER C.Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine[J]. Arquivos de Neuro-Psiquiatria, 2004, 62(3-B): 784-788.
[15] BRUCKE T, WOBER C, PODREKA I, et al.D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. aspect study[J]. Journal of Cerebral Blood Flow & Metabolism Official Journal of the International Society of Cerebral Blood Flow & Metabolism, 1995, 15(3): 513-521.
[16] NEGROTTI A, CALZETTI S.A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism[J]. Movement Disorders, 1997, 12(1): 107-117.
[17] TEIEVE HA, TROIANO AR, GERMINIANI FM, et al.Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis[J]. Parkinsonism and Related Disorders, 2004, 10(4): 243-245.
[18] WANG JL, ZHANG XM, ZHANG B, et al.Safety of medications for cardiovascular diseases in community clinics[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(7): 744-748.

1例盐酸曲美他嗪片致合并肾功能不全老年患者帕金森综合征的药学监护

Pharmaceutical care for a case of Parkinson's syndrome caused by trimetazidine hydrochloride tablets in an elderly patient with renal insufficiency

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.